News & Insights

Discover the latest updates on our company and investments in life science

Sciety news

Cartana is acquired by 10x Genomics for 425 MSEK

PRESS RELEASE. The American biotechnology company 10x Genomics acquires the Swedish company Cartana, which was financed by the Sciety investment syndicate two years ago. Three years after launch, the Swedish biotechnology company Cartana will be part of the Nasdaq-listed American company 10x Genomics––the market leader in single-cell analysis technology. The

Read More »

Interview with Mats Nilsson, serial entrepreneur at SciLifeLab

Sciety had the opportunity to ask a few questions to Mats Nilsson, professor at SciLifeLab and co-founder of EMPE Diagnostics and several other biotechnology companies. In the interview he talks about EMPE Diagnostics’ planned establishment in India and and about the need for diagnostic tools in order to use the drugs that are available. He gives an insight into SciLifeLab as the platform for developing ideas and also his view on the role of research in society.

Read More »

Interview with Pavan Asalapuram, co-founder of EMPE Diagnostics

Sciety talks with Pavan Asalapuram, co-founder of EMPE Diagnostics, a company that develops rapid diagnostic solutions for infectious diseases, with a special focus on tuberculosis––a major public health problem in big parts of the world. EMPE’s test can within two hours identify whether a person has TB and whether it

Read More »

Sciety is a capital partner specialising in life science and healthcare, offering services in capital raising and related areas. Sciety may currently have, may previously have had or may in the future be engaged by companies mentioned in our communications or operating in the sectors described, and may hold ownership interests in such companies. Sciety receives remuneration for its services, including commissions in connection to capital raises. Our communication is intended for informational purposes only and does not constitute personal investment advice. We do not guarantee the accuracy, completeness or timeliness of the information provided. Investment decisions should not be based solely on this communication.